Skip to content
naulon
Not checkedNot checked for notices yet.

Switching between TNFα antagonists in rheumatoid arthritis: personal experience and review of the literature

M. Di Franco, L. Magrini, S. Truglia and 5 more

Reumatismo · 2011

doi:10.4081/reumatismo.2009.107 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

The treatment of rheumatoid arthritis (RA) has evolved over the past decade with the introduction of anti-tumor necrosis factor (TNF) α agents, which allowed remarkable advances in controlling signs and symptoms of inflammation and in slowing joint destruction (1-3). However, some patients do not respond or show suboptimal response to the currently available anti- TNFα agents (infliximab, etanercept, and adalimumab) used either as monotherapy or in combination with methotrexate. Furthermore, patients who respond initially may lose efficacy over time (4) or develop adverse events.

Abstract licence: CC BY-NC

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.